Last reviewed · How we verify
Placebos morning
Placebos are inert substances that produce therapeutic effects through psychobiological mechanisms including expectation, conditioning, and natural disease course.
Placebos are inert substances that produce therapeutic effects through psychobiological mechanisms including expectation, conditioning, and natural disease course. Used for Control arm in phase 3 clinical trials.
At a glance
| Generic name | Placebos morning |
|---|---|
| Sponsor | Basque Health Service |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebos work primarily through the placebo effect, wherein patient expectations and belief in treatment activate neural pathways that can modulate pain perception, immune function, and symptom severity. The effect is enhanced by clinical context, provider interaction, and ritualistic elements of treatment administration. Placebos are commonly used as control comparators in clinical trials to isolate the true pharmacological efficacy of active drugs.
Approved indications
- Control arm in phase 3 clinical trials
Common side effects
- Nocebo effects (adverse events attributed to placebo)
Key clinical trials
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Effects of NAC on Symptoms of CHR Patients (NA)
- Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial (PHASE3)
- Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects (PHASE1)
- Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis (PHASE2)
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- A Study of HS-10518 in Healthy Adult Premenopausal Females in China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebos morning CI brief — competitive landscape report
- Placebos morning updates RSS · CI watch RSS
- Basque Health Service portfolio CI